UV Spectrophotometric Determination of Metformin Hydrochloride Extended-Release Tablets: Principle,

UV spectrophotometry is a rapid, economical, and pharmacopoeia-recognized technique for quantifying metformin hydrochloride in extended-release tablets, supporting assay, content uniformity, and in vitro release testing. This article outlines the analytical principle, sample preparation, operating conditions, validation requirements, and typical applications of UV spectrophotometric determination for metformin hydrochloride sustained-release tablets. The guidance is suitable for pharmaceutical manufacturers, accredited third-party laboratories, and research institutions operating under ISO/IEC 17025-aligned quality systems.

Technical Overview

Metformin hydrochloride (1,1-dimethylbiguanide hydrochloride; CAS No. 1115-70-4; molecular formula C4H11N5·HCl; molecular weight 165.63) is a biguanide oral antihyperglycemic agent and a first-line pharmacological treatment for type 2 diabetes mellitus. Extended-release (sustained-release) tablets, commonly available in strengths of 500 mg and 750 mg, employ hydrophilic matrix or other rate-controlling technologies to release the drug gradually, reducing dosing frequency and improving gastrointestinal tolerability.

UV-Visible spectrophotometric determination exploits the strong ultraviolet absorption of the biguanide chromophore. In aqueous media, metformin hydrochloride exhibits a maximum absorbance (λmax) at approximately 232–233 nm, with a specific absorbance (E1%, 1 cm) of approximately 798. Quantification follows the Beer–Lambert law (A = ε·b·c), under which absorbance is directly proportional to concentration within a validated linear range. Because the method requires only a spectrophotometer, matched quartz cuvettes, and common reagents, it is widely adopted for routine quality control, dissolution monitoring, and formulation screening.

The procedure is consistent with the general ultraviolet-visible spectrophotometry chapters of major pharmacopoeias, including the Chinese Pharmacopoeia (ChP), the United States Pharmacopeia (USP), and the European Pharmacopoeia (EP). Analytical method validation should conform to ICH Q2(R2), and testing is routinely performed by manufacturers and accredited third-party laboratories operating under ISO/IEC 17025 quality management systems.

Testing Samples

Finished Commercial or Pilot Batches

Representative samples of metformin hydrochloride extended-release tablets drawn from production batches, pilot-scale batches, or scale-up confirmation batches. For assay determination, a minimum of 20 tablets is typically weighed and comminuted to a homogeneous powder; the mean unit weight is recorded for content calculations.

Individual Dosage Units

Single tablets assayed independently for uniformity of dosage units testing. Typically ten units are analyzed, and individual contents are used to compute the acceptance value in accordance with the applicable pharmacopoeial general chapter.

Laboratory-Prepared and Stability Samples

Experimental formulations produced during formulation development, such as hypromellose-based hydrophilic matrix tablets, as well as retained samples stored under ICH Q1A(R2) accelerated (40 °C / 75% RH) and long-term (25 °C / 60% RH) conditions for stability evaluation.

Reference Standard and Placebo

A qualified metformin hydrochloride chemical reference substance or in-house working standard with an assigned purity value, and a placebo matrix containing all excipients without active ingredient. The placebo is essential for verifying method specificity and preparing blank corrections.

Testing Items

UV spectrophotometric determination of metformin hydrochloride extended-release tablets typically covers the following quality attributes:

• Assay (content): quantitative determination of metformin hydrochloride, generally within 95.0%–105.0% of the labeled amount.
• Uniformity of dosage units: assessment of content uniformity or weight variation with corresponding acceptance values.
• In vitro release (dissolution) testing: multi-time-point cumulative release profiles that characterize the extended-release behavior of the dosage form.
• In-process controls: blend uniformity and intermediate product checks during compression and coating operations.
• Stability-indicating content determination: assay of samples under stress and formal storage conditions as part of stability programs.
• Method validation studies: specificity, linearity, range, accuracy, precision, detection limit, quantitation limit, solution stability, and robustness.

Testing Methods

Instruments and Reagents

A qualified double-beam UV-Vis spectrophotometer equipped with matched 1 cm quartz cuvettes; an analytical balance with 0.1 mg readability; Class A volumetric glassware; an ultrasonic bath; and a dissolution apparatus (paddle or basket) meeting pharmacopoeial specifications. Reagents include purified water, pH 6.8 phosphate buffer as dissolution medium, and a metformin hydrochloride reference standard. All equipment should be calibrated and maintained under an ISO/IEC 17025-compliant or equivalent quality system.

Assay Sample Preparation

Twenty tablets are accurately weighed and ground to a fine, homogeneous powder. A portion of powder equivalent to approximately 100 mg of metformin hydrochloride is transferred to a volumetric flask, dissolved in purified water with the aid of sonication, and diluted to volume to yield a stock solution of about 1 mg/mL. The solution is filtered, discarding the initial filtrate, and an aliquot is further diluted with water to a final concentration of approximately 8–10 µg/mL. A reference standard solution of identical nominal concentration is prepared in parallel, and a placebo solution is prepared in the same manner to verify the absence of excipient absorption.

Measurement Conditions

The spectrophotometer is zeroed against a purified water blank. A full scan from 200 to 400 nm is performed on the standard solution to confirm the absorption maximum at approximately 233 nm. Absorbance of standard and sample solutions is then measured in duplicate at 233 nm using matched quartz cuvettes, with absorbance values preferably between 0.3 and 0.8 to minimize photometric error. Content is calculated using either the external standard comparison method, based on the absorbance ratio of sample to standard, or the absorption coefficient method, incorporating average tablet weight, dilution factors, labeled strength, and standard purity.

In Vitro Release Testing

Dissolution testing is performed in pH 6.8 phosphate buffer (typically 1000 mL, maintained at 37 ± 0.5 °C) using the paddle apparatus at 100 rpm, although the basket apparatus may be applied to specific formulations. Aliquots are withdrawn at predetermined time points, for example 1, 3, and 10 hours, filtered through 0.45 µm membranes, and assayed spectrophotometrically at 233 nm against a medium blank. Volumes are replaced to maintain constant medium volume, and cumulative percent release is corrected for sampling. Representative acceptance profiles restrict initial release, for example to not more than about 30% within the first hour, while requiring substantially complete release, commonly not less than 80%–85%, at the final time point, as specified in the applicable monograph or registered specification.

Method Validation

In accordance with ICH Q2(R2), the following parameters are validated: specificity, demonstrated by negligible placebo absorbance at 233 nm, typically below 1–2% of the analytical signal; linearity over approximately 2–16 µg/mL with a correlation coefficient of not less than 0.999; accuracy demonstrated by recovery of 98.0%–102.0% from spiked placebo; precision with relative standard deviation of not more than 2.0% for repeatability; detection and quantitation limits derived from signal-to-noise or σ/slope statistics; and robustness against small variations in wavelength, dilution scheme, and instrument parameters. Solution stability is confirmed over the anticipated analysis duration.

Applications

UV spectrophotometric determination of metformin hydrochloride extended-release tablets serves a broad range of pharmaceutical development and quality control purposes:

• Routine quality control: batch release testing of assay and uniformity of dosage units in pharmaceutical manufacturing facilities.
• Formulation development: screening of hydrophilic matrix polymers, fillers, and coatings by monitoring content consistency and release behavior.
• Release kinetics modeling: fitting UV dissolution data to zero-order, first-order, Higuchi, and Korsmeyer–Peppas models to characterize the extended-release mechanism.
• Stability programs: monitoring of content and release profiles for samples stored under ICH long-term, intermediate, and accelerated conditions.
• Generic product development: multi-profile dissolution comparison between test and reference products using the similarity factor (f2) in biorelevant media.
• Regulatory support: generation of analytical data for registration dossiers and verification of pharmacopoeial compliance.
• Research and education: quantitative laboratory exercises in pharmaceutical analysis and spectrophotometric method development studies.

FAQ

Why is 233 nm selected as the detection wavelength?

Aqueous metformin hydrochloride exhibits its absorption maximum at approximately 232–233 nm owing to the biguanide chromophore. Measuring at λmax provides the highest sensitivity and minimizes wavelength-related error; the exact maximum should be confirmed by spectral scanning on each instrument prior to measurement.

Do tablet excipients interfere with the UV measurement?

Hydrophilic matrix polymers such as hypromellose and common fillers generally show negligible absorbance at 233 nm. Specificity is nevertheless verified experimentally with a placebo solution, and filtration removes insoluble matrix residues. If interference is demonstrated, a chromatographic method should be used instead.

What advantages does UV spectrophotometry offer over HPLC for this product?

UV spectrophotometry is faster, less expensive, sparing in solvent consumption, and simple to operate, making it well suited to high-throughput dissolution testing and routine assay. HPLC provides greater selectivity for related substances and stability-indicating applications and is preferred when degradation products or excipients absorb significantly at the analytical wavelength.

How is the extended-release behavior confirmed?

Multi-time-point dissolution profiles in pH 6.8 buffer demonstrate controlled release: restricted initial release, progressive release over the dosing interval, and near-complete release at the final time point. Profiles are compared against monograph limits or, for generic products, against the reference product using the similarity factor.

What are the typical acceptance criteria for assay and uniformity?

Assay results generally fall within 95.0%–105.0% of the labeled amount of metformin hydrochloride. Uniformity of dosage units is evaluated using the pharmacopoeial acceptance value scheme, for example USP General Chapter 905 or the corresponding ChP general chapter, under which the acceptance value must not exceed 15.

Which standards govern the method?

The analytical procedure aligns with the ultraviolet-visible spectrophotometry general chapters of the Chinese Pharmacopoeia, USP, and EP, dissolution general chapters such as USP General Chapter 711, and the validation requirements of ICH Q2(R2). Laboratory competence is commonly demonstrated through ISO/IEC 17025 accreditation.